All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
EHA 2019 | What effect does gilteritinib have on FLT3 mutated relapsed/refractory AML?
Featured:
Alexander PerlAt the 24th Congress of the European Hematology Association (EHA), Alexander Perl from the University of Pennsylvania, US, presented the data from the ADMIRAL phase III trial of gilteritinib, a selective FLT3 inhibitor, for relapsed or refractory (R/R) acute myeloid leukemia (AML).
Patients were randomized 2:1 to receive either gilteritinib or one of four standard salvage chemotherapy treatments. The favorable outcomes of gilteritinib observed in this trial (increased complete response rate and overall survival) led to its FDA approval for R/R AML.
What effect does gilteritinib have on FLT3 mutated relapsed/refractory AML?